FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Schnitzer

Research Profile

Chemicals & Drugs

Disorders

Procedures

Double-Blind Method

Concepts & Ideas

Co-author Network

Publications

TOP 3
Javeria A Hashmi; Lejian Huang; Thomas J Schnitzer; Marwan N Baliki; Alex T Baria; A Vania Apkarian
Brain networks predicting placebo analgesia in a clinical trial for chronic back pain.
Thomas J Schnitzer; Rachel Welbel; Nicole Wysocki; Bindu Manyam; Meghan Romba; Danielle Barkema; Sheena Bhuva; James Griffith; Victoria Lent; Sarah Linn
Calcaneal quantitative ultrasound compared with hip and femoral neck dual-energy x-ray absorptiometry in people with a spinal cord injury.
Thomas J Schnitzer; P Supanwanid; Richard L Harvey; L Maskala-Streff; S Hillary Nack; E Roth
Bone mineral density in patients with stroke: relationship with motor impairment and functional mobility.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Schnitzer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Javeria A Hashmi; Lejian Huang; Thomas J Schnitzer; Marwan N Baliki; Alex T Baria; A Vania Apkarian
Brain networks predicting placebo analgesia in a clinical trial for chronic back pain.
Pain 2012;153(12):2393-402.
2012: Thomas J Schnitzer; Rachel Welbel; Nicole Wysocki; Bindu Manyam; Meghan Romba; Danielle Barkema; Sheena Bhuva; James Griffith; Victoria Lent; Sarah Linn
Calcaneal quantitative ultrasound compared with hip and femoral neck dual-energy x-ray absorptiometry in people with a spinal cord injury.
PM & R : the journal of injury, function, and rehabilitation 2012;4(10):748-55.
2012: Thomas J Schnitzer; P Supanwanid; Richard L Harvey; L Maskala-Streff; S Hillary Nack; E Roth
Bone mineral density in patients with stroke: relationship with motor impairment and functional mobility.
Topics in stroke rehabilitation 2012;19(5):436-43.
2012: Marwan N Baliki; Howard Fields; Kristina M Herrmann; Lejian Huang; Bogdan Petre; Thomas J Schnitzer; Souraya Torbey; A Vania Apkarian
Corticostriatal functional connectivity predicts transition to chronic back pain.
Nature neuroscience 2012;15(8):1117-9.
2012: Thomas J Schnitzer; W Tad Archambault; William T Ellison; John E Ervin; Heidi B Fezatte; Richard D Gordon; Doug M Haselwood; Jeffrey R Lisse; Jean-Pierre Pelletier; Scott B Phillips; Allan R Sampson; Joel E Bernstein
Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension.
The Journal of rheumatology 2012;39(3):610-20.
2011: Thomas J Schnitzer; Bruno Seriolo; Lillian Tseng; I Dan Dattani; Alan Moore; Rosemary Rebuli; Peter Sallstig; Hartmut Schneider; Thomas Maxwell
A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
Clinical rheumatology 2011;30(11):1433-46.
2011: Elle L Parks; Thomas J Schnitzer; Marwan N Baliki; Paul Geha; Jeffrey Katz; A Vania Apkarian
Brain activity for chronic knee osteoarthritis: dissociating evoked pain from spontaneous pain.
European journal of pain (London, England) 2011;15(8):843.e1-14.
2011: Mona Lisa Chanda; Thomas J Schnitzer; Matthew D Alvin; A Vania Apkarian
Pain characteristic differences between subacute and chronic back pain.
The journal of pain : official journal of the American Pain Society 2011;12(7):792-800.
2011: Thomas J Schnitzer; Nancy E Lane; C Birbara; M D Smith; S L Simpson; M T Brown
Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2011;19(6):639-46.
2011: Thomas J Schnitzer; Marc C Hochberg; Christopher E Marrero; Brigitte Duquesroix; Hayet Frayssinet; Maarten Beekman
Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study.
Seminars in arthritis and rheumatism 2011;40(4):285-97.
2011: Marwan N Baliki; William R Bauer; Thomas J Schnitzer; A Vania Apkarian
Brain morphological signatures for chronic pain.
PloS one 2011;6(10):e26010.
2010: Thomas J Schnitzer
New pharmacologic approaches in the management of osteoarthritis.
Arthritis care & research 2010;62(8):1174-80.
2010: Thomas J Schnitzer; A Kivitz; H Frayssinet; B Duquesroix
Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2010;18(5):629-39.
2009: Jon Karlsson; Aldina Pivodic; Diana Aguirre; Thomas J Schnitzer
Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
The Journal of rheumatology 2009;36(6):1290-7.
2009: Thomas Roth; Janet M Price; David A Amato; Robert P Rubens; James M Roach; Thomas J Schnitzer
The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study.
Primary care companion to the Journal of clinical psychiatry 2009;11(6):292-301.
2008: Marwan N Baliki; Paul Geha; Rami Jabakhanji; Norm Harden; Thomas J Schnitzer; A Vania Apkarian
A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis.
Molecular pain 2008;4():47.
2008: Thomas J Schnitzer
Introduction: from basic biology to therapeutic potential.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2008;16 Suppl 2():S1.
2007: Jared A Greenberg; Elliot J Roth; Lisa-Ann Wuermser; Orit Almagor; Thomas J Schnitzer
Osteoporosis treatment for patients with stroke.
Topics in stroke rehabilitation 2007;14(2):62-7.
2006: Steven S Smugar; Thomas J Schnitzer; Arthur L Weaver; Bernard R Rubin; Adam B Polis; Andrew M Tershakovec
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Current medical research and opinion 2006;22(7):1353-67.
2005: Chin Lee; Elke Hunsche; Robert Balshaw; Sheldon X Kong; Thomas J Schnitzer
Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
Arthritis and rheumatism 2005;53(4):510-8.
2005: Thomas J Schnitzer; Arthur L Weaver; Adam B Polis; Richard A Petruschke; Gregory P Geba
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
The Journal of rheumatology 2005;32(6):1093-105.
2005: Thomas J Schnitzer; Xavier Gitton; Sumedha Jayawardene; Victor S Sloan
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Current medical research and opinion 2005;21(1):151-61.
2004: Chin Lee; Walter L Straus; Robert Balshaw; Suna Barlas; Suzanne Vogel; Thomas J Schnitzer
A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
Arthritis and rheumatism 2004;51(5):746-54.
2004: Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet 2004;364(9435):675-84.
2004: Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Lancet 2004;364(9435):665-74.
2004: Thomas J Schnitzer; Jannie Beier; Piet Geusens; Paul Hasler; Sanjay K Patel; Ingo Senftleber; Xavier Gitton; Alan Moore; Victor S Sloan; Gyula Poór
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2004;51(4):549-57.
2004: Thomas J Schnitzer; Aimee Ferraro; Elke Hunsche; Sheldon X Kong
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain.
Journal of pain and symptom management 2004;28(1):72-95.
2003: Thomas J Schnitzer; Sheldon X Kong; Jeffrey H Mitchell; Panagiotis Mavros; Douglas J Watson; James M Pellissier; Walter L Straus
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Clinical therapeutics 2003;25(12):3162-72.
2002: R Rizzoli; Susan L Greenspan; G Bone; Thomas J Schnitzer; N B Watts; Silvano Adami; A J Foldes; C Roux; Michael A. Levine; B Uebelhart; Arthur C Santora; Amarjot Kaur; C A Peverly; John J Orloff
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2002;17(11):1988-96.
2002: Keith M Gottesdiener; Thomas J Schnitzer; C Fisher; B Bockow; J Markenson; A Ko; Lisa DeTora; S Curtis; LA Geissler; Barry J Gertz
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
Rheumatology (Oxford, England) 2002;41(9):1052-61.
2002: Thomas J Schnitzer
Update of ACR guidelines for osteoarthritis: role of the coxibs.
Journal of pain and symptom management 2002;23(4 Suppl):S24-30; discussion S31-4.
2002: Gregory P Geba; Arthur L Weaver; Adam B Polis; Mary E Dixon; Thomas J Schnitzer
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
JAMA : the journal of the American Medical Association 2002;287(1):64-71.
2002: Thomas J Schnitzer; Marc C Hochberg
COX-2-selective inhibitors in the treatment of arthritis.
Cleveland Clinic journal of medicine 2002;69 Suppl 1():SI20-30.
2001: Thomas J Schnitzer; Sheldon X Kong; Panagiotis Mavros; Walter L Straus; Douglas J Watson
Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
Clinical therapeutics 2001;23(12):1984-98.
2001: James A Bolognese; Elliot W Ehrich; Thomas J Schnitzer
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
The Journal of rheumatology 2001;28(12):2700-4.
2001: Thomas J Schnitzer
Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.
Clinical therapeutics 2001;23(3):313-326; discussion 311-2.
2001: MG Murphy; S Weiss; Michael R McClung; Thomas J Schnitzer; KA Cerchio; J Connor; David Krupa; Barry J Gertz
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
The Journal of clinical endocrinology and metabolism 2001;86(3):1116-25.
2001: Thomas J Schnitzer
Cyclooxygenase-2--specific inhibitors: are they safe?
The American journal of medicine 2001;110(1A):46S-49S.
2000: Thomas J Schnitzer; W L Gray; R Z Paster; Marc Kamin
Efficacy of tramadol in treatment of chronic low back pain.
The Journal of rheumatology 2000;27(3):772-8.
2000: Thomas J Schnitzer; Henry G Bone; G Crepaldi; Silvano Adami; Michael R McClung; D Kiel; Dieter Felsenberg; Robert R Recker; Richard P Tonino; C Roux; A Pinchera; A J Foldes; Susan L Greenspan; Michael A. Levine; Ronald Emkey; Arthur C Santora; Amarjot Kaur; Desmond E Thompson; John Yates; John J Orloff
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Aging (Milan, Italy) 2000;12(1):1-12.
1999: Elliot W Ehrich; Thomas J Schnitzer; Harris H McIlwain; R Levy; F Wolfe; M Weisman; Q Zeng; B Morrison; James A Bolognese; BC Seidenberg; Barry J Gertz
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
The Journal of rheumatology 1999;26(11):2438-47.
1999: Thomas J Schnitzer; KE Truitt; R Fleischmann; P Dalgin; J Block; Q Zeng; James A Bolognese; BC Seidenberg; Elliot W Ehrich
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
Clinical therapeutics 1999;21(10):1688-702.
1999: Thomas J Schnitzer; Marc Kamin; William H Olson
Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study.
Arthritis and rheumatism 1999;42(7):1370-7.
1998: Kenneth G Saag; Ronald Emkey; Thomas J Schnitzer; J P Brown; Federico Hawkins; Stefan Goemaere; G Thamsborg; Uri A Liberman; Pierre D Delmas; MP Malice; M Czachur; Anastasia G Daifotis
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
The New England journal of medicine 1998;339(5):292-9.
1998: Thomas J Schnitzer
Non-NSAID pharmacologic treatment options for the management of chronic pain.
The American journal of medicine 1998;105(1B):45S-52S.
1998: Leena Sharma; D E Hurwitz; Eugene Thonar; JA Sum; M E Lenz; Dorothy D Dunlop; Thomas J Schnitzer; G Kirwan-Mellis; Thomas P Andriacchi
Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritis.
Arthritis and rheumatism 1998;41(7):1233-40.
1993: Thomas J Schnitzer; J M Popovich; Gunnar B J Andersson; Thomas P Andriacchi
Effect of piroxicam on gait in patients with osteoarthritis of the knee.
Arthritis and rheumatism 1993;36(9):1207-13.
1991: G V Campion; F McCrae; Thomas J Schnitzer; Mary Ellen Lenz; Paul Dieppe; Eugene Thonar
Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee.
Arthritis and rheumatism 1991;34(10):1254-9.
1991: Eugene Thonar; D M Manicourt; J Williams; Mary Ellen Lenz; M B Sweet; Thomas J Schnitzer; L Otten; Tibor T Glant; Klaus E Kuettner
Circulating keratan sulfate: a marker of cartilage proteoglycan catabolism in osteoarthritis.
The Journal of rheumatology. Supplement 1991;27():24-6.
1991: J Barone-Varelas; Thomas J Schnitzer; Q Meng; L Otten; Eugene Thonar
Age-related differences in the metabolism of proteoglycans in bovine articular cartilage explants maintained in the presence of insulin-like growth factor I.
Connective tissue research 1991;26(1-2):101-20.
1989: J A Block; Thomas J Schnitzer; Gunnar B J Andersson; Mary Ellen Lenz; R Jeffery; T W McNeill; Eugene Thonar
The effect of chemonucleolysis on serum keratan sulfate levels in humans.
Arthritis and rheumatism 1989;32(1):100-4.
1988: M B Sweet; A Coelho; CM Schnitzler; Thomas J Schnitzer; Mary Ellen Lenz; I Jakim; Klaus E Kuettner; Eugene Thonar
Serum keratan sulfate levels in osteoarthritis patients.
Arthritis and rheumatism 1988;31(5):648-52.